Athenex intends to use the net revenue of the proposed provision to continue expanding its advertising infrastructure, execute label expansion methods for Oral Paclitaxel, advance the progression of its candidate products, invest in its CMC progression for its candidate products and production infrastructure, and Finance the company’s working capital and other general purposes.
SVB Leerink, RBC Capital Markets and Evercore ISI act as co-accountants and Oppenheimer
The securities described above are presented through Athenex in accordance with a previous registration on Form S-3 (File No. 333-227492) that was filed with the Securities and Exchange Commission (the “SEC”) on September 24. of 2018 and has come into effect upon filing. Provision will be made solely through a written prospectus and a supplemental prospectus component that is part of the registration matrix. An initial supplement to the prospectus relating to the terms of the Offer and describing the terms of the Offer has been filed with the SEC and will be available from the SEC’s online page. at www. sec. gov. A supplement to the final prospectus and the accompanying prospectus related to this feature will be filed with the SEC and will be available at www. sec. gov. If obtained, copies of the final Supplemental Prospectus and accompanying prospectus may also be received from: SVB Leerink LLC, Attention: Syndicate Decomponentment, One Federal Street, 37th Floor, Boston, MA 02110, via telephone at 1-800-808-7525, ext. 6218, or by email to syndicate@svbleerink. com; RBC Capital Markets, LLC, AttnArray: Equity Syndicate, 200 Vesey Street, 8th Floor, New York, NY 10281, by phone at (877) 822-4089, or by email at equityprospectus@rbccm. com; and Evercore Group LLC, Attention: Equity Capital Markets, 55 East 52nd Street, 36th Floor, New York, New York 10055, or by phone at (888) 474-0two hundred, or by email at ecm. prospectus@evercore. com
At Athenex, Inc. Founded in 2003, Athenex, Inc. es a clinically staged global biopharmaceutical company committed to Inc. es leader in the discovery, progression and advertising of next-generation cancer drugs. Athenex is organized around 3 platforms, adding an oncology innovation platform, an advertising platform and a global source chain platform. The company’s existing clinical portfolio is derived from 4 other platform technologies: (1) Orascovery, founded on the Glycoprotein P inhibitor, (2) inhibition of src kinase, (3) T-mobiles designed through T mobile receptors (TCR-T) and (4) arginine deprivation therapy. Athenex workers around the world are committed to the lives of cancer patients by creating more active and tolerable treatments. Athenex has offices in Buffalo and Clarence, New York; Cranford, New Jersey; Houston, Texas; Chicago, Ill. , Hong Kong; Taipei, Taiwan; several sites in Chongqing, China; Manchester, United Kingdom; Guatemala, Guatemala and Buenos Aires, Argentina.
Forward-Looking Statements Except for the above information, all statements, expectations, and assumptions contained in this press release are forward-looking statements. These forward-looking statements are sometimes known through terms such as “anticipate”, “believe”, “consider”, “continue”, “may also simply”, “estimate”, “expect”, “explore”, “anticipate”, “target”, “Orientation”, “target”, “likely”, “possibly”, “plan”, “prospective”, “anticipate”, “initial”, “likely”, “assignment”, “promising”, “search “Array” Should “,” will “,” would “and similar expressions. Actual effects may differ materially from those expressed or implied in the forward-looking statements. Important points that may also cause actual effects to vary materially include: the level of progression of our primary clinical applicants and similar threats related to drug progression, clinical trials, regulation, production and marketing; our ability to download and maintain regulatory approvals for our product applicants; our reliance on third parties for good fortune in certain areas of the Athenex business; our history of operating losses and desire for more capital to continue operating; uncertainties surrounding our ability to comply with and access the investment terms under our investment agreements; the threats and insecurities relevant to the COVID-19 pandemic and its prospects have an effect on our operations, money flow and monetary condition; our ability to integrate acquired assets and businesses into our existing operations; competition; high-level asset threats; similar threats to foreign industry and China; the threat of production slowdown or disruption or other disruptions at our Chongqing facility; and other threat points discussed from time to time in our SEC filings. All information provided in this press release is as of the date of this press release and we do not assume any legal responsibility and do not intend to update those forward-looking statements unless required by law.
contacts
Daniel Lang, MD, Business Development and Corporate Communications Email: danlang@athenex. com
Jacqueline Li Business and Investor Relations Email: jacquelineli@athenex. com